Trial Profile

A phase III global pivotal study of L606, a sustained-release inhaled formulation of treprostinil

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Aug 2024 According to a Liquidia Technologies media release, data from this study will be presented at PHA 2024 International PH Conference and Scientific Sessions in Indianapolis, Indiana.
13 Mar 2024 According to a Liquidia Technologies media release, Company is preparing to initiate the global PH-ILD study by the end of 2024.
30 Jan 2024 According to a Liquidia Technologies media release, the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 through February 3, 2024, in London, England.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com